News | November 24, 2015

Biosense Webster Acquires Coherex Medical LAA Occluder Technology

The addition of the Coherex WaveCrest left atrial appendage occluder to the company’s portfolio expands range of treatment options for patients with atrial fibrillation

coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device company based in Salt Lake City, Utah focused on the development of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System. The device is designed to permanently occlude the LAA in high-risk atrial fibrillation (Afib) patients to help reduce the incidence of stroke caused by the migration of blood clots formed in the LAA, which is recognized as the source of blood clots in approximately 90 percent of patients who have Afib.

“The addition of the Coherex WaveCrest System complements our comprehensive portfolio of therapeutic solutions for patients suffering from atrial fibrillation who not only suffer from reduced quality of life, but also face a significantly greater risk of a stroke,” said Shlomi Nachman, company group chairman. "As the exclusive distributor of this system in regions outside of the U.S. since 2013, we are confident it will be well-differentiated in the market.”

Afib is associated with a five-fold increased risk of stroke and prevention in patients with Afib represents a large unmet clinical need. This acquisition reinforces the company's commitment to providing innovative, minimally invasive therapies for the treatment of Afib, which affects over 3 million patients in the United States and 20 million worldwide.

"The Coherex WaveCrest System offers substantial benefits for patients with atrial fibrillation who are at high risk for stroke, particularly for those who are contraindicated to anticoagulants and would therefore, be unprotected from the risk of cardio embolism," said Alex Martin, president and CEO, Coherex Medical. "We are excited that this technology will be coupled with Biosense Webster’s market leading therapies and look forward to bringing this innovative solution to more patients worldwide who stand to benefit from reduced risk of stroke.”

The Coherex WaveCrest LAA occlusion system received CE mark in September 2013. It is not available for investigational use or commercial distribution in the United States at this time.

For more information: www.biosensewebster.com

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init